Finally, AWS shared its efforts on the health care front as well. On Nov. 29, it made Amazon Omics generally available. That platform analyzes genome data to predict disease predisposition or drug efficacy, for example. It’s regulatory-compliant and HIPAA eligible, Selipsky said. Overall, Amazon Omics will “help target diseases with even more modernized therapy,” Selipsky said.
Cybersecurity advisory warns of hackers' malicious use of #RMM. @CISACyber dlvr.it/ShYRwg https://t.co/zsBvQWqOYY
Reaction to #Intel earnings coming in fast and furious. Find out what investors are saying, and how CEO Pat Gelsing… twitter.com/i/web/status/1…
Our latest #GatelyReport looks at #cybersecurity M&A, investment with @progresspartner, @cyber_advisory, @FBI Hive… twitter.com/i/web/status/1…
.@channelsmart says plan and boost client #retention efforts to reduce #churn. dlvr.it/ShXvhj https://t.co/4jyHPCjTBn
The CEO of @Mitel discusses the likely outcomes of buying @Atos Unify. Note: @RingCentral will play a role post acq… twitter.com/i/web/status/1…
.@msftsecurity surpasses $20 billion in annual revenue, analysts say it's a formidable #cybersecurity market conten… twitter.com/i/web/status/1…
The adoption of cloud-based services ☁️ has spiked in the last few years and is among the top growth segments. See… twitter.com/i/web/status/1…
[email protected], @NICECXone, @lumencpp, @CiscoPartners joined @IntelisysCorp and partners for a day of marketing worksho… twitter.com/i/web/status/1…
